Semaglutide (Ozempic / Wegovy / Rybelsus)
PharmaceuticalLast reviewed on May 15, 2026 by SupStaq
Not medical advice. This content is general, evidence-based information and is not a substitute for professional medical advice, diagnosis, or treatment.
The discrepancy is explained by the very strong clinical evidence from large-scale trials such as SELECT (n = 17,604) [s9] and STEP 5 [s6], while community users frequently cite subjective side effects, access barriers, and costs as their primary concerns [c1, c2].
Unlock full information
Dosages, side effects, studies and more, free after registration.
Register for freeRating Scales
TL;DR
Semaglutide is the most evidence-backed weight management drug currently available: −15 to −17% body weight in Phase III RCTs, plus a 20% reduction in MACE events in high-risk cardiovascular patients — consistently replicated across multiple independent trials. The downsides are real: nausea and vomiting affect the majority of users, muscle mass loss is documented at higher doses, and weight regain after discontinuation is the norm rather than the exception. Compounded semaglutide from grey-market sources carries serious safety and legal risks. Anyone starting semaglutide should treat it as a long-term intervention paired with lifestyle changes — not a short-term fix.
Description
Synthetic GLP-1 analogue for the treatment of type 2 diabetes and obesity; reduces body weight, HbA1c, and cardiovascular risk [s1, s5, s9].
Semaglutide is a long-acting, synthetic analogue of the endogenous incretin hormone GLP-1 (glucagon-like peptide-1). It is administered once weekly by subcutaneous injection (Ozempic® 0.25–1 mg for T2DM; Wegovy® 2.4 mg for obesity) or taken orally once daily (Rybelsus® 3–14 mg for T2DM) [s1, s12]. The subcutaneous formulation achieves a bioavailability of approximately 89%, whereas the oral formulation achieves only 0.4–1% due to gastric acid degradation; the latter therefore contains substantially higher amounts of active substance [s12]. In the STEP-1 to STEP-5 trials (total n > 4,500 participants), Wegovy® (2.4 mg s.c.) reduced body weight after 68–104 weeks by an average of approximately 15–17% versus placebo [s5, s6]. In the SELECT trial (n = 17,604, non-diabetic patients with obesity and pre-existing cardiovascular disease), semaglutide 2.4 mg s.c. reduced the risk of major adverse cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction, stroke) by 20% versus placebo [s9]. In type 2 diabetes, semaglutide 1 mg s.c. improved HbA1c by approximately 1.5 percentage points and body weight by approximately 4–6 kg compared to placebo or other GLP-1 agonists [s7]. Following discontinuation of semaglutide, studies observed a mean weight regain of 0.8 kg/month, with a projected return to baseline weight after approximately 1.5 years [s11]. A significant decrease in lean body mass was documented by DXA measurements at the 2.4 mg dose [s10].
Legal Status (DE)
{'ema_cv_indication_status': 'EMA-CHMP recommendation dated 25 July 2024: update of the Wegovy label to include reduction of MACE (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) in adults with established cardiovascular disease and overweight/obesity (BMI ≥27 kg/m²) without type 2 diabetes. Source: s20. ', 'gkv_reimbursement_note': 'No statutory health insurance (GKV) reimbursement data available on the EMA EPAR page. Reimbursement status in Germany remains regulated at the national level (AMNOG/G-BA); based on currently available information, no routine GKV reimbursement for the obesity indication in Germany. '}
Mechanism of Action
Semaglutide binds selectively and with high affinity to the GLP-1 receptor (GLP-1R), a G protein-coupled receptor expressed in the pancreas, intestine, heart, kidneys, and central nervous system [s1, s2]. Pancreatic effects: GLP-1R activation in beta cells stimulates glucose-dependent insulin secretion while simultaneously inhibiting glucagon secretion from alpha cells, resulting in improved glycaemic control without hypoglycaemia risk during monotherapy [s2, s14]. Gastrointestinal effects: Semaglutide slows gastric emptying (gastroparesis-like effect), increases satiety, and reduces food intake [s1, s3]. Central nervous system effects: Semaglutide crosses the blood-brain barrier and activates GLP-1 receptors in the hypothalamus (appetite regulation), the nucleus tractus solitarius (NTS), and reward centres (mesolimbic system), leading to reductions in hunger and food craving [s2, s4]. Dopaminergic signalling pathways are also modulated, suggesting a possible role in addictive and reward behaviour [s2]. Cardiovascular effects: Direct GLP-1R activation at the heart, combined with indirect effects via weight reduction, blood pressure lowering, lipid improvement, and anti-inflammatory mechanisms, contributes to MACE reduction [s9]. Structural characteristics: Semaglutide shares 94% sequence homology with native GLP-1 but is conjugated to albumin via a C18 fatty acid chain, extending the half-life to approximately 7 days and enabling once-weekly dosing [s1].
Dosing
Typ-2-Diabetes (Ozempic® sc.)
- Dose
- Starting dose 0.25 mg sc. weekly for 4 weeks; then 0.5 mg weekly; escalation to 1 mg possible
- Frequency
- 1× wöchentlich
- Route
- injektion-subkutan
- Duration
- fortlaufend
- Timing
- On a fixed day of the week, at any time of day
- With food
- optional
Adipositas / Gewichtsmanagement (Wegovy® sc.)
- Dose
- Starting dose 0.25 mg sc. weekly; stepwise dose escalation over 16 weeks to target dose 2.4 mg weekly
- Frequency
- 1× wöchentlich
- Route
- injektion-subkutan
- Duration
- fortlaufend
- Timing
- On a fixed day of the week, at any time of day
- With food
- optional
Typ-2-Diabetes (Rybelsus® oral)
- Dose
- Starting dose 3 mg daily for 30 days; then 7 mg daily; escalation to 14 mg possible
- Frequency
- 1× täglich
- Route
- oral
- Duration
- fortlaufend
- Timing
- Fasted, at least 30 minutes before the first food/drink of the day, with max. 120 ml water
- With food
- vermeiden
Maximum dose: 2.4 mg s.c. weekly (Wegovy®), or 1 mg s.c. weekly (Ozempic® for T2DM), or 14 mg daily orally (Rybelsus®). Exceeding approved doses is not recommended and is associated with an increased risk of adverse effects [s14].
Semaglutide is available by prescription only. Slow dose titration is used to reduce gastrointestinal side effects [s14]. Compounded semaglutide without regulatory approval carries substantial safety and legal risks [s13, s17].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Übelkeit Reported in STEP trials in >40% of participants at 2.4 mg; occurs primarily with dose escalation and typically resolves after weeks [s5]. | häufig | leicht |
| Erbrechen Common GI adverse effect in clinical trials; discontinuation rate due to GI events approx. 2.86% [s8]. | häufig | leicht |
| Durchfall According to Wikipedia reference in >5% of patients; gastrointestinal motility alteration via GLP-1R activation [s2]. | häufig | leicht |
| Verstopfung Delayed gastric emptying can lead to constipation; reported in >5% of subjects in clinical trials [s14]. | häufig | leicht |
| Bauchschmerzen Abdominal discomfort as part of the gastrointestinal side effect profile [s14]. | häufig | leicht |
| Akute Pankreatitis 5 cases of pancreatitis reported in clinical studies; warning included in the Prescribing Information [s13, s8]. | selten | schwer |
| Schilddrüsen-C-Zell-Tumoren (in Tierversuchen) Demonstrated in rodent studies; relevance to humans unclear; no statistically significant association shown in human studies to date [s13, s14]. | theoretisch | schwer |
| Hypoglykämie (bei Kombination mit Insulin oder Sulfonylharnstoffen) In combination with other antidiabetic agents; no relevant hypoglycemia risk with semaglutide monotherapy [s14]. | gelegentlich | moderat |
| Akute Nierenschädigung Post-marketing reports of acute kidney injury (some requiring dialysis), presumably due to dehydration from severe vomiting [s13]. | selten | schwer |
| Diabetische Retinopathie-Komplikationen Documented in patients with pre-existing retinopathy and rapid HbA1c reduction [s14]. | selten | moderat |
| Menstruationsstörungen und Temperaturveränderungen Described in Reddit analyses; not captured as primary endpoints in clinical trials [c1]. | selten | leicht |
| Abnahme der fettfreien Muskelmasse (Lean Mass) DXA measurements in the SLIM LIVER Study and STEP-1 show significant lean mass reduction at the 2.4 mg dose [s10]. | gelegentlich | moderat |
Contraindications
Contraindicated due to theoretical risk of C-cell tumors; absolute contraindication per regulatory approval [s13, s14].
GLP-1 agonists are associated with pancreatitis; contraindicated in patients with a history of pancreatitis [s14].
Anaphylactic reactions possible; absolute contraindication [s13, s14].
Insufficient human data; animal studies demonstrate embryotoxic effects; discontinuation at least 2 months before planned pregnancy is recommended [s14].
GLP-1 agonists increase the risk of cholelithiasis and cholecystitis; caution in active disease [s14].
Rapid HbA1c reduction may trigger retinopathy complications; close ophthalmological monitoring required [s14].
Semaglutide further delays gastric emptying; may lead to dehydration and renal injury [s13].
Interactions
Synergistic
Combination therapy improves glycemic control and HbA1c reduction; no clinically relevant pharmacokinetic interaction demonstrated [s18].
STEP trials demonstrate superior weight reduction with semaglutide combined with structured behavioral interventions [s5, s6].
Berberine activates AMPK and lowers blood glucose, potentially complementing the glucose-lowering effect of semaglutide. Both substances together may improve insulin sensitivity and metabolic control. Medical supervision is essential due to the increased risk of hypoglycemia.
BPC-157 may promote gut health and attenuate gastrointestinal side effects of semaglutide (nausea, gastrointestinal motility disorders). It supports nutrient absorption, which may be impaired by semaglutide-induced delayed gastric emptying.
Myo-inositol and D-chiro-inositol improve insulin sensitivity and may synergistically support the blood glucose-lowering effect of semaglutide. This combination may be particularly beneficial in PCOS and insulin resistance.
Alpha-lipoic acid improves insulin sensitivity and may complement the glucose-lowering effect of semaglutide. The combination may be particularly beneficial in diabetic neuropathy. Blood glucose monitoring at the initiation of combined use is recommended.
Caution
Increased risk of hypoglycemia with combination; dose reduction of concomitant medication may be required [s14].
Delayed gastric emptying may affect absorption; no clinically relevant interaction demonstrated in pharmacokinetic studies, however monitoring is recommended [s18].
Semaglutide showed no clinically relevant interaction with warfarin in studies; nevertheless, INR monitoring after treatment initiation is recommended [s18].
Both substances lower blood glucose via different mechanisms, significantly increasing the risk of hypoglycemia — particularly with concomitant use of insulin or sulfonylureas. Regular blood glucose monitoring and medical supervision are mandatory.
Ashwagandha may lower blood glucose levels and affect cortisol and thyroid hormone levels. In combination with semaglutide, this may increase the risk of hypoglycemia and should be closely monitored.
Alpha-lipoic acid may lower blood glucose and increase the risk of hypoglycemia when used in combination with semaglutide. Regular blood glucose monitoring is particularly necessary at the start of treatment.
Studies
Tier A: High Evidence
Outcome: Percent change in body weight from baseline
Effect Size: −14.9% semaglutide 2.4 mg vs. −2.4% placebo (p<0.001)
Outcome: Sustained weight reduction over 2 years
Effect Size: −15.2% semaglutide vs. −2.6% placebo at 104 weeks
Outcome: HbA1c reduction and weight reduction in T2DM
Effect Size: Superior HbA1c and weight reduction vs. other GLP-1 RAs
Outcome: MACE (cardiovascular death, non-fatal MI, stroke)
Effect Size: HR 0.80 (95% CI 0.72–0.90); p<0.001; MACE reduction 20%
Outcome: Weight reduction in overweight/obesity without diabetes
Effect Size: Significant weight reduction; discontinuation due to AEs in 2.86%
Tier B: Moderate Evidence
Outcome: Change in lean body mass (DXA)
Effect Size: Significant lean mass loss with semaglutide 2.4 mg s.c.
Outcome: Pharmacokinetic interaction with metformin, warfarin, atorvastatin, digoxin
Effect Size: No clinically relevant interaction at steady-state co-dosing
Outcome: Weight regain after discontinuation of GLP-1 RAs
Effect Size: Semaglutide 2.4 mg: pooled MD −5.15 kg (95% CI: −5.27 to −5.03); weight regain approx. 0.8 kg/month after discontinuation
Tier C: Low Evidence
Outcome: CNS mechanisms of weight reduction by semaglutide
Effect Size: Activation of diverse GLP-1R populations; modulation of food intake, reward behavior, and energy homeostasis
Community Evidence
Top reported benefits
- Significant weight loss without experiencing hunger
- Reduced cravings for sweets and high-calorie foods
- Improved fasting blood glucose in type 2 diabetes
- Mood improvement through perceived gain of control over eating
- Reduced alcohol cravings (addiction modulation)
Top reported issues
- Severe nausea, particularly with dose escalation
- Vomiting and diarrhea as reasons for discontinuation
- Weight regain after discontinuation as a major concern
- High costs (300–400 €/month) without statutory health insurance coverage
- Supply shortages and difficulties in procurement
- Fear of thyroid cancer and pancreatitis
Community users report side effects not captured as primary endpoints in clinical trials: menstrual changes, cold intolerance, depression, and anxiety [c1]. Grey-market and compounded products are discussed but also regarded as risky [c1, c2]. Microdosing protocols are being experimentally explored within the community without a clinical evidence base.
Scientific Sources
- Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review
Ghusn W, De la Rosa A, Sacoto D, et al. (2022). Annals of PharmacotherapyBPMID:35730296DOI - Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study
Newsome PN, Ambery P, Flint A, et al. (2025). PMC / Journal of Hepatology (published online)ADOI - Rebound or Retention: A Meta-Analysis of Weight Regain After the Discontinuation of GLP-1 Receptor Agonists and Other Anti-obesity Drugs
Shetty R, Balachandran M, Patil S, et al. (2025). PMC (preprint / published)ALink - Comparative Effectiveness and Safety of Oral Versus Subcutaneous Semaglutide in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Al-Saleh A, Almutairi AR, Al-Aqeel S, et al. (2025). PMC / Diabetes CareALink - Ozempic (semaglutide) Prescribing Information – FDA Label 2025
Novo Nordisk, FDA (2025). FDA accessdataALink - Wegovy (semaglutide) injection – FDA Prescribing Information (Label)
Novo Nordisk, FDA (2023). FDA accessdataALink - Ozempic® – Krankenkasse & Kostenübernahme
GoLighter Redaktion (2024). golighter.deBLink - Abnehmspritzen Ozempic und Wegovy: Zahlen die Krankenkassen?
krankenkassen.de Redaktion (2024). krankenkassen.deBLink - Peptide, Abnehmspritzen & Co.: Grauzone oder Strafbarkeit?
Anwalt.de Redaktion (2024). anwalt.deBLink - Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects
Hausner H, Derving Karsbøl J, Holst AG, et al. (2017). Clinical PharmacokineticsAPMID:28527067DOI - FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
U.S. Food and Drug Administration (2024). FDA.govALink - GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling
Falk S, Kästner A, Bærentzen SL, et al. (2023). NeuroImage: Clinical / ScienceDirectCDOI - Wegovy (semaglutide) — EPAR: European Public Assessment Report (inkl. CHMP-Zulassung zur kardiovaskulären Risikoreduzierung, Juli 2024)
Unbekannt (2024). CLink - How does semaglutide work? (Mayo Clinic Diet overview)
Mayo Clinic Diet Editorial Staff (2024). Mayo Clinic Diet BlogBLink - Semaglutide lowers body weight in rodents via distributed neural pathways
Gabery S, Salinas CG, Paulsen SJ, et al. (2020). JCI InsightCPMID:32213703DOI - Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Wilding JPH, Batterham RL, Calanna S, et al. (2021). New England Journal of MedicineAPMID:33567185DOI - Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey WT, Batterham RL, Bhatta M, et al. (2022). Nature MedicineAPMID:36216945DOI - Glycemic Control, Weight Management, Cardiovascular Safety, and Cost-Effectiveness of Semaglutide for Patients with Type 2 Diabetes Mellitus: A Rapid Review and Meta-analysis of Real-World Studies
Shaman AM, Soran H, Younis N, et al. (2024). PharmacotherapyAPMID:38372036DOI - Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial
Qin W, Li S, Chen X, et al. (2024). Diabetes, Obesity and MetabolismAPMID:38037277DOI - Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT Trial)
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). New England Journal of MedicineAPMID:37952131DOI
Community Sources
Storage
Unopened
Pre-filled pens (Ozempic®, Wegovy®) should be stored in a refrigerator at 2–8 °C; do not freeze [s14].
Opened
After first use, stable at room temperature (max. 30 °C) for up to 6 weeks (Ozempic®) or 4 weeks (Wegovy®) [s14].
Notes
Protect from direct sunlight and heat sources. Rybelsus® (tablets) should be stored at room temperature (15–30 °C) in the original packaging [s14].